To understand the role of GSK-3β in tau pathogenesis in AD, we determined the expression of GSK-3β in frontal cortices from 7 AD and 7 age- and postmortem interval–matched control brains that were obtained ≤3.5 h after death (Table S1) by Western blots developed with R127, an antibody against residues 364–377 of GSK-3β (referred to the longest isoform). Here, MAPT is linked to Alzheimer disease.